Select your country

Internationalization of OTC brands: STADA agrees to early termination of license agreement with Sanofi for head lice lotion Hedrin

  • 18/01/2018
  • Investor News

Bad Vilbel, January 18, 2018 – STADA Arzneimittel AG is advancing the internationalization of its OTC brand business. On January 12, 2018, the company reached an agreement with Sanofi on the early termination of the license agreement for its Hedrin products in Belgium, Spain, and Portugal. Sanofi had acquired these from the STADA subsidiary Thornton & Ross.

Now the STADA companies Eurogenerics (Belgium), Ciclum Farma (Portugal) and Laboratorio STADA (Spain) have taken over the commercialization of the head lice and nits products as from January 17, 2018. The nationally established brand names Silikom (Belgium), Piky (Portugal), and Neositrin (Spain), under which Hedrin is marketed in these countries by Sanofi, have been acquired, as have the associated Internet domains.

“Alongside biosimilars, the internationalization of successful products is one of STADA’s business areas with the greatest growth potential. Hedrin is the Group’s first truly pan-European product and demonstrates the path we would like to take with other strong products such as Fultium, ViruProtect or Ladival,” said STADA’s CEO Dr. Claudio Albrecht, explaining the reasons for the early termination of the sales agreement with Sanofi.

With a share of 18% in terms of packs sold, Hedrin is Europe’s market leader in products for the treatment of head lice*. In addition to the domestic UK market, it is currently sold in 12 other European countries – in some cases under other brand names. Hedrin Once and Hedrin Protect&Go have been available in Germany since July 2017.

* Source: IMS year to December 2015. Total for UK, Spain, France, Germany, Italy, Poland, Belgium, Portugal, Czech Republic, Switzerland, Austria, Hungary, Slovakia.


About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.

Additional information for journalists
STADA Arzneimittel AG / Media Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: press@stada.de

Additional information for capital market participants
STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de